On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....